AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02362672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181 BID tablets
Description: NKTR-181 tablets 100-400 mg twice daily (BID)
Study NCT02860858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreous aflibercept injection
Study NCT02362672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match NKTR-181 BID tablets
Description: Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
Study NCT05397392 — intervention group
Intervention type: OTHER
Intervention: guideline recommended routine treatment
Study NCT01651520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with 11C-Flumazenil
Description: PET with 11C-Flumazenil.
Study NCT01651520 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PET with 11C-Flumazenil
Description: PET with 11C-Flumazenil.
Study NCT02093117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: continuous positive airway pressure of 30 cm of water for 30 seconds
Study NCT02093117 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham recruitment maneuver
Description: Continuous positive airway pressure of 5 cm of water for 30 seconds
Study NCT04010240 — intervention group
Intervention type: OTHER
Intervention: Retrospective cohort
Description: Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
Study NCT02950870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir-Paritaprevir-Ritonavir
Description: The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
Study NCT02950870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: The patient will be treated daily with Dasubavir 500 mg total dose
Study NCT02950870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Patients will be treated with ribavirin if necessary.
Study NCT01645358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet (Starmed)
Description: The helmet is a kind of interface similar to a hood to deliver NIV
Study NCT01645358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Face mask (Respironics)
Description: The total face mask is the classical interface for NIV delivery
Study NCT02091479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFH Early group
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Study NCT02637076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem
Description: single 3.0 gram dose
Study NCT04979234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina- Endoscopic Sleeve Gastroplasty
Description: Endoscopic gastric reduction
Study NCT02091479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFH Late group
Description: Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily).
Study NCT02736227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Withdrawal and Everolimus Monotherapy
Description: During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
Study NCT04147754 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Preoperative epidural anesthesia at physician discretion
Study NCT02135185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: custom work endurance
Description: Experimental: Rehabilitation effort
Study NCT02135185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary management adapted to the nutritional status
Description: dietary management adapted to the nutritional status
Study NCT04147754 — intervention group
Intervention type: PROCEDURE
Intervention: Intrathecal morphine
Description: Preoperative intrathecal morphine at physician discretion
Study NCT04147754 — intervention group
Intervention type: PROCEDURE
Intervention: Erector spinae block
Description: Preoperative erector spinae block at physician discretion
Study NCT02863445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-based emergency contraception 1.5 mg
Description: Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
Study NCT02863445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-based emergency contraception 3.0mg
Description: Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
Study NCT02410525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]PF-06427878
Description: Single administration via intravenous infusion of 20 ug \[11C\]PF-06427878 on Day 1 of all 3 Periods
Study NCT04979234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Multidisciplinary follow up
Study NCT01486277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat, 12 mg
Description: Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
Study NCT02341599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6183
Description: MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
Study NCT00119795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Increase Physical Activity to 150 min/wk
Study NCT00119795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Lose 7-10% of body weight and increase physical activity to 150 min/wk
Study NCT00119795 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Lectures on information relevant to successful aging
Study NCT04230993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sea water solution
Description: Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
Study NCT03359070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaconazole
Description: Application of 1 gram on the lesion.
Study NCT04230993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sea water solution
Description: Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
Study NCT01105078 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Flow rate
Description: Different flow rate during cardiopulmonary bypass
Study NCT03404947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: For one exercise session, participants will be asked to ingest a quantity of ethanol (in the form of vodka) sufficient to maximally stimulate liver alcohol metabolism.
Study NCT01515865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl
Description: dose at subject's current dose level
Study NCT03359070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Nitrate
Description: Application of 1 gram on the lesion.
Study NCT04539574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7 Tesla Magnetic Resonance Imaging
Description: Undergo 7T MRI
Study NCT01515865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of matching placebo
Study NCT03636971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with mannitol
Description: single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
Study NCT03636971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with sorbitol
Description: single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
Study NCT03636971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: single shot injection of saline, same volume
Study NCT02410525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878 10 mg
Description: Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
Study NCT02410525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878 600 mg
Description: Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to \[11C\]PF-06427878 administration
Study NCT04539574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00929084 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The Survivor Stories Tablet
Description: The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
Study NCT04309045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: Today, the most well-known and established treatment for borderline personality disorder is Dialectical Behavior Therapy (DBT) that developed by Marsha Linhan in the 1990s. DBT is currently used in other disorders such as: eating disorders, addictions, impulse control problems and bipolar disorder. Various studies have found a beneficial effect for this treatment in various areas: decreased suicidal thoughts and attempts and self-harm behaviors, improvements in suicide attempts, anger levels, impulsive behaviors, depressive symptoms, The use of drugs, the percentage of dropouts from treatment, number Hospitalization and general function.
Study NCT04309045 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DDP
Description: DDP treatment is part of a trend of dynamic therapies to treat borderline personality disorder. The DDP focuses on deficiencies in the emotional experience processing and is performed in the form of weekly, individual sessions with a trained therapist over a 12-18 month period. Treatment is based on the need to correct three neurocognitive functions responsible for adaptive processing of emotional experiences: association (the ability to recognize, understand their existence, and experience a sequence of emotional experiences), attribution (the ability to make complex attributions about the self and others), and the ability to make realistic attribution, about the self and the other. Interventions that activate these three functions are the basis for DDP treatment.
Study NCT04309045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Patients on the waiting list for treatment, or patients in the hospital under routine care.
Study NCT02658630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot + TTT exercise
Description: The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
Study NCT03013023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BS
Description: NNS, FT, positional support, and oral sucrose feeding
Study NCT03013023 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Routine NICU care
Study NCT03013023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PITP
Description: Parents will learn to regulate infant responses while implementing caregiving activities.
Study NCT03013023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BS+PITP
Description: Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
Study NCT03439592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: collection of fecal material
Description: in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.
Study NCT04015635 — intervention group
Intervention type: OTHER
Intervention: None involved
Description: NO intervention
Study NCT03124316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anticipated regret
Description: Induce awareness of future regret about the unwanted behaviour
Study NCT03124316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Material incentive
Description: Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
Study NCT03124316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving
Description: Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
Study NCT05226520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental probiotic product
Description: Probiotic supplementation
Study NCT05226520 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo
Study NCT04279639 — intervention group
Intervention type: BEHAVIORAL
Intervention: qigong
Description: Patients of the Pain Management Unit either experience usual treatment, or usual treatment plus qigong practice.
Study NCT02259712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Description: 45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
Study NCT02259712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education.
Description: The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant.
Study NCT02259712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic education.
Description: The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant.
Study NCT02259712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic-perineal physiotherapy
Description: 45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
Study NCT02259712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic-perineal physiotherapy
Description: 45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
Study NCT02259712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy assessment
Description: Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
Study NCT02259712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy assessment
Description: Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
Study NCT03858881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROJECT PERSONALITY
Description: PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits
Study NCT03858881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR PERSONALITY PROJECT
Description: The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
Study NCT03858881 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SHARING FEELINGS PROGRAM
Description: The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.